Information  X 
Enter a valid email address

Medica Group PLC (MGP)


Friday 28 May, 2021

Medica Group PLC

Director/PDMR Shareholding

RNS Number : 2474A
Medica Group PLC
28 May 2021

Medica Group PLC


Director / PDMR Shareholding


Medica Group PLC (the "Company") announces that on 28 May 2021, the PDMRs listed below were granted options over ordinary shares of 0.2p each in the Company under the Company's Performance Share Plan 2017 at a nil exercise price:


Name of PDMR

Number of shares subject to option

Stuart Quin


Richard Jones


Kevin Terrins


Sarah Burns


Marc O'Brien

Caroline Byrne

Rob Lavis





The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation, and set out more details of the transactions.



Details of PDMR



1.  Stuart Quin

2.  Richard Jones

3.  Kevin Terrins

4.  Sarah Burns

5.  Marc O'Brien

6.  Caroline Byrne

7.  Rob Lavis



Reason for notification


Position / status

1.  Chief Executive Officer

2.  Chief Financial Officer

3.  Business Development Director

4.  Chief Operating Officer

5.  Chief Technical Officer

6.  Managing Director, Ireland

7.  Medical Director



Initial notification / amendment

Initial notification in each case


Details of the Issuer



Medica Group PLC





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) have been conducted


Description of the financial instrument

Ordinary shares of 0.2p each in the capital of the Company ("Shares")


Nature of the transaction

Grant of options to acquire Shares pursuant to the Company's Performance Share Plan 2017


Price(s) and volume

Option Price nil in each case

1. 213,071

2. 150,403

3. 93,071

4. 93,071

5. 112,802

6.  53,969

7.  103,309



Aggregated information



Date of the transaction

28 May 2021


Place of the transaction

Outside a trading venue





This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t